23andFda

The controversy re: @23andMe is a health issue, but also a data one. See what this means for the #openaccess debate: http://t.co/qDLYmlwLys

— datascience@berkeley (@BerkeleyData) January 29, 2014

Roever Genia FDA shuts down @23andMe but it's your data. You own it. People will ship it abroad for analysis #PMWC14 @FreeBRCA #FreeTheData
— Jonathan Hirsch (@JonathanHirsch) January 28, 2014

#23andMe may spend some time 'in the wilderness,' but they'll be back. HT to @iApothecary for the heads up on the opinion piece. (3/3)
— John Humphreys (@johnpharmd) January 27, 2014

The authors of that #JAMA viewpoint were rather charitable toward #FDA, IMO. Fact is, FDA itself very much needs to be disrupted. (2/n)
— John Humphreys (@johnpharmd) January 27, 2014

"[#23andMe's] PGS is example of a disruptive product that challenged the FDA’s existing regulatory framework." http://t.co/C8Jppc6Uae (1/n)
— John Humphreys (@johnpharmd) January 27, 2014